Moderna Net Tangible Assets from 2010 to 2025

MRNA Stock  USD 31.73  2.12  6.26%   
Moderna's Net Tangible Assets are increasing over the years with slightly volatile fluctuation. Overall, Net Tangible Assets are expected to go to about 23.1 B this year. Net Tangible Assets is the total assets of Moderna minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2016-12-31
Previous Quarter
16.9 B
Current Value
13.4 B
Quarterly Volatility
7.3 B
 
Covid
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna's main balance sheet or income statement drivers, such as Interest Expense of 12.5 M, Selling General Administrative of 1.2 B or Total Revenue of 4.8 B, as well as many indicators such as Price To Sales Ratio of 4.69, Dividend Yield of 1.0E-4 or PTB Ratio of 1.39. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules.
  
Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Latest Moderna's Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of Moderna over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Moderna's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

Moderna Net Tangible Assets Regression Statistics

Arithmetic Mean6,362,403,668
Coefficient Of Variation146.95
Mean Deviation8,207,681,770
Median1,174,810,000
Standard Deviation9,349,847,632
Sample Variance87419650.7T
Range23.6B
R-Value0.85
Mean Square Error26153388.4T
R-Squared0.72
Significance0.000032
Slope1,667,286,739
Total Sum of Squares1311294761.2T

Moderna Net Tangible Assets History

202523.1 B
202422 B
202219.1 B
202114.1 B
20202.6 B
20191.2 B
20181.5 B

About Moderna Financial Statements

Moderna stakeholders use historical fundamental indicators, such as Moderna's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Moderna investors may analyze each financial statement separately, they are all interrelated. For example, changes in Moderna's assets and liabilities are reflected in the revenues and expenses on Moderna's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Tangible Assets22 B23.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.85)
Earnings Share
(9.28)
Revenue Per Share
8.427
Quarterly Revenue Growth
(0.66)
Return On Assets
(0.15)
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.